Monocentric, exploratory study comparing 68Ga-RM2 PET / CT to 68Ga-PSMA-617 PET / CT in prostate cancer patients with different metastatic risks, candidates for total prostatectomy (Etude monocentrique, exploratoire, comparant la TEP/TDM au 68Ga-RM2 à la TEP/TDM au 68Ga-PSMA-617 chez des patients atteints de cancers de la prostate de différents risques métastatiques, candidats à une prostatectomie totale}
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs 68-Ga-PSMA-617 (Primary) ; Gallium 68 RM2 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Acronyms UROPET
- 12 Jun 2020 This trial is completed (Global End Date: 11 Dec 2019), according to European Clinical Trials Database record.
- 09 Jun 2020 Status changed from recruiting to completed.
- 18 Dec 2019 Planned End Date changed from 31 Dec 2019 to 25 Jun 2020.